[Sublingual immunotherapy with cat epithelial extract. Personal experience].
Because cats are a common pet in many houses and tourist complexes in the Canary Islands, sensitization to cat epithelium is a frequent problem. A total of 19.2% of patients with intrinsic asthma are sensitized to cat epithelium. In the Canary Islands, the percentage of sensitization among patients with a household cat is 18.1%, which higher is higher than in the rest of Spain (11.9). Many patients with extrinsic asthma sensitized to house dust mites undergo conventional subcutaneous immunotherapy but evolution is unsatisfactory due to sensitization to cat epithelium (whether a cat is present or not). The aim of this study was to evaluate the clinical effectiveness of sublingual immunotherapy with extract of cat epithelium in monosensitized patients with perennial allergic rhinitis and/or bronchial asthma. Forty patients monosensitized to cat epithelium were selected. Of these, 20 were administered sublingual immunotherapy and another 20 received placebo. The following evaluation was carried out in both groups: in vivo and in vitro: symptom score, skin tests, nasal challenge with cat epithelium, specific IgE determination, specific IgG4 and eosinophilic cationic protein. After 1 year of treatment the cumulative dose was 3.6 micrograms of Fe ld I, equivalent to 10 ng/drop. Duration of treatment was 365 days. Our conclusions, based on our patients in the Canary Islands, were the following: 1. Sublingual Fel d I therapy is effective after 1 year of treatment. 2. There were no modifications in IgE, eosinophilic cationic protein or skin tests. 3. An increase in IgG4 occurred which was related to clinical improvement. 4. In general, tolerance was good, except in one patient who presented urticaria and sublingual pruritus. 5. In polysensitized patients, sublingual immunotherapy to cat epithelium is complementary to immunotherapy to dermatophagoides.
Sánchez Palacios
A
A
Unidad de Alergología, Hospital Universitario Insular de Gran Canaria, Las Palmas de Gran Canaria.
Schamann
F
F
García
J A
JA
D000286:Administration, Sublingual; D000485:Allergens / Q000008:administration & dosage / Q000627:therapeutic use*; D000818:Animals; D000918:Antibody Specificity; D001249:Asthma / Q000209:etiology / Q000628:therapy*; D001798:Blood Proteins / Q000032:analysis; D002415:Cats / Q000276:immunology*; D003888:Desensitization, Immunologic; D004311:Double-Blind Method; D047091:Eosinophil Granule Proteins; D004847:Epithelial Cells / Q000276:immunology; D006023:Glycoproteins / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D007073:Immunoglobulin E / Q000276:immunology; D007074:Immunoglobulin G / Q000276:immunology; D009299:Nasal Provocation Tests; D012221:Rhinitis, Allergic, Perennial / Q000209:etiology / Q000628:therapy*; D012260:Ribonucleases; D012882:Skin Tests; D016896:Treatment Outcome
D000485:Allergens; D001798:Blood Proteins; D047091:Eosinophil Granule Proteins; D006023:Glycoproteins; D007074:Immunoglobulin G; D007073:Immunoglobulin E; D012260:Ribonucleases; C059296:Fel d 1 protein, Felis domesticus